| 摘要: |
| 目的：系统评价玉屏风制剂联合匹多莫德治疗儿童反复呼吸道感染的临床疗效和安全性，为临床循证医学研究提供参考。方法：计算机检索PubMed、EMBase、中国生物医学文献数据库（CBM）、中国知网（CNKI）、维普数据库（VIP）和万方数据库，收集常规治疗+玉屏风制剂联合匹多莫德（试验组）对比单用常规治疗或常规治疗+匹多莫德（对照组）治疗儿童反复呼吸道感染（RRTI）的随机对照试验（RCT），检索时间为2000年1月至2018年3月，提取资料并评价质量后，采用RevMan 5.2软件进行Meta分析。结果：共纳入12篇文献，1 175例患儿。Meta分析结果显示，试验组总有效率高于对照组（RR=1.25，95% CI 1.19~1.32，P<0.01）；退热时间、咳嗽缓解时间、肺部啰音和扁桃体红肿消失时间均短于对照组（P均<0.01）；治疗后免疫球蛋白水平（IgA、IgM和IgG）和T淋巴细胞水平（CD3+、CD4+和CD4+/CD8+）均高于对照组（P均<0.01）。所有文献均未报道不良反应。结论：玉屏风制剂联合匹多莫德能够显著改善儿童RRTI的免疫功能及临床体征，从而提高总有效率。 |
| 关键词: 玉屏风 匹多莫德 儿童 反复呼吸道感染 免疫功能 Meta分析 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2020.07.008 |
|
| 基金项目: |
|
| Meta-Analysis of Yupingfeng Combined with Pidomomod in the Treatment of Children with Recurrent Respiratory Infection |
| He Renzhong, Cen Min, Wang Guan, Guo Jian |
| (Huangshi Central Hospital of Edong Medical Group, Affiliated Hospital of Hubei University Technology, Hubei Huangshi 435000, China) |
| Abstract: |
| Objective: To systematically evaluate the clinical efficacy and safety of Yupingfeng combined with pidomomod in the treatment of children with recurrent respiratory infections, so as to provide reference for the clinical treatment. Methods: PubMed, EMBase, CBM, CNKI, VIP and Wanfang database were retrieved to collect the randomized controlled trials (RCTS) of conventional therapy + Yupingfeng in combination with pidomomod (experimental group), conventional therapy alone, conventional therapy + pidomomod (control group) in the treatment of children with repeated respiratory infections. The retrieval time was from Jan. 2000 to Mar. 2018. After extracting the data and evaluating the quality, Meta-analysis was performed by using RevMan 5.2 software. Results: Totally 12 literature were collected, including 1,175 children. Meta-analysis results showed that the total effective rate of the experimental group was higher than that of the control group (RR=1.25, 95%CI from 1.19 to 1.32, P<0.01); the duration of fever, relief time of cough, disappearance time of lung rales and tonsil redness were shorter than those of the control group (P<0.01). After treatment, immunoglobulin levels (IgA, IgM and IgG) and T lymphocyte levels (CD3+, CD4+ and CD4+/CD8+) of the experimental group were higher than those of the control group (P<0.01). No adverse drug reactions were reported in all literature. Conclusion: Yupingfeng combined with pidotimod can significantly improve the immune level of children with recurrent respiratory infections and clinical signs, thereby increasing the total effective rate |
| Key words: Yupingfeng pidomomod children recurrent respiratory tract infections immune function Meta-analysis |
